Home › Trial NCT05232851
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
- Trial IDNCT05232851
- StatusActive Not Recruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorMayo Clinic
- Enrollment20
- Start date2022-06-16
- ConditionsClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Human Papillomavirus-Related Carcinoma · Locally Advanced Oropharyngeal Carcinoma · Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 · Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.